Skip to main content
. 2018 Sep 28;104(3):599–608. doi: 10.3324/haematol.2018.195669

Figure 2.

Figure 2.

Flowchart for the assessment of human proteome cross-matching and missense mutation hemophilia A inhibitor risk. The flowchart shows the process by which the presence, or otherwise, of a novel peptide-MHC surface is determined given a specific combination of endogenous F8 missense mutation and human leukocyte antigen isoform. tFVIII: therapeutic factor VIII; FVIII: factor VIII; TCR: T-cell receptor.